Objective: To investigate differences between Hispanics and non-Hispanic whites diagnosed with and treated for renal cell carcinoma in an equal access healthcare system. Methods: We carried out a retrospective cohort study within the Kaiser Permanente healthcare system using records from renal cell carcinoma cases. Ethnicity was identified as Hispanic or non-Hispanic whites. Patient characteristics, comorbidities, tumor characteristics and treatment were compared. Overall and disease-specific survival was calculated, and a Cox proportion hazard model estimated the association of ethnicity and survival. Results: A total of 2577 patients (2152 non-Hispanic whites, 425 Hispanic) were evaluated. Hispanics were diagnosed at a younger age (59.6 years vs 65.3 years). Clear cell renal cell carcinoma was more prevalent, whereas papillary renal cell carcinoma was less common among Hispanics. Hispanics had a lower American Joint Committee on Cancer stage (I/II vs III/IV) than non-Hispanic whites (67.4% vs 62.2%). Hispanics were found to have a greater frequency of comorbidities, such as chronic kidney disease and diabetes, but were more likely to receive surgery. The presence of metastases, nodal involvement, increased tumor size, non-surgical management, increasing age and Hispanic ethnicity were independent predictors of worse cancer-specific outcome. Conclusions: Within an equal access healthcare system, Hispanics seem to be diagnosed at younger ages, to have greater comorbidities and to present more frequently with clear cell renal cell carcinoma compared with non-Hispanic white patients. Despite lower stage and greater receipt of surgery, Hispanic ethnicity seems to be an independent predictor of mortality. Further work is necessary to confirm these findings.
Introduction
According to the 2014 USA Census Bureau, 55 million Americans, or 17% of the total USA population, were identified as having Hispanic ethnicity, making people of Hispanic origin the nation's largest ethnic minority. 1 Approximately 37% of Hispanics are born outside the USA, and the largest populations of Hispanics are from Mexico (63%), Puerto Rico (9%), Central America (8%), South America (6%) and Cuba (4%). 1 Between 2000 and 2010, the Hispanic population grew by 43%, fourfold the growth of the total population. 1 As certain ethnic and racial groups have specific cancer predispositions that are due to complex genetic and environmental factors, it is imperative we understand how different illnesses affect Hispanics in the USA.
Ethnic variations in cancer outcome might also widely vary depending on the specific type of cancer. For the most common cancers, such as prostate, female breast, colorectal and lung cancer, the incidence and death rates are lower among Hispanics than among non-Hispanic whites. However, for other cancers, such as for stomach, cervix, liver, acute lymphocytic leukemia and gallbladder cancer, Hispanics have higher disease incidence and mortality. 2 Despite RCC being a highly prevalent disease, there have been limited data comparing the outcomes of Hispanics with RCC to non-Hispanic whites. 1, 3 There has been a rising trend in the reported cases of RCC amongst all racial groups, with a disproportionate increase amongst several minority groups. 4 Studies have shown various epidemiological risk factors that predispose for RCC, including male sex, CKD, hypertension, and greater BMI. [5] [6] [7] [8] [9] The incidence of several of these risk factors differs between racial groups, which might partly explain some of the recent epidemiological trends. Besides the changing incidence, there has been concern that survival disparities also exist, partially explained by access to care.
A thorough evaluation into racial disparities in kidney cancer survival requires understanding of comorbidities, tumor characteristics and treatment. In the USA, access to healthcare significantly differs by race and SES, which can influence outcomes due to barriers to treatment. 10 The USA has a private-based healthcare system, except for those who are eligible for government assistance, including the disabled or those aged ≥65 years (Medicaid and Medicare, respectively). This is an important consideration to make, as the Hispanic community in the USA has, on average, a lower SES when compared with non-Hispanic whites. 11 Health disparities have previously been attributed to the lack of health insurance, and with an increased likelihood of being uninsured, it becomes challenging to determine the true contributors to cancer survival outcome. 12 Survival analysis using a large population-based program, such as the SEER database, might not account for differences in barriers to care amongst patients of different ethnicities. Therefore, it is reasonable to assume that survival disparities that are related to access to care might be minimized in a population within a single-payer healthcare system. 13, 14 By using a single-payer healthcare database where all patients have comparable access to care, we evaluated whether survival differences exist while controlling for demographics, tumor characteristics and comorbidities.
Methods

Study design
To evaluate racial disparities between Hispanics and non-Hispanic whites in a single-payer healthcare system, we carried out a case-control study of RCC nested within a retrospective cohort of members of the Northern California Kaiser Permanente System. 15 All members of the Kaiser Permanente System receive similar access to care regardless of SES based on healthcare-wide, practice-based guidelines. Study participants were included if they had been diagnosed with histologically confirmed, RCC (International Classification of Disease 9th edition, site code C64.9) between 1998 and 2008, and received care within this prepaid healthcare system. Data used to report demographics were obtained from membership databases, which include age, race/ethnicity (self-described) and sex. The cancer data were obtained from the Kaiser Permanente Cancer Registry, which reports directly to the SEER 
Statistical analysis
We evaluated differences in clinicopathological and comorbidity variables that might explain or confound the relationships between Hispanic ethnicity and adverse cancer outcomes. Continuous and categorical variables were analyzed with Kruskal-Wallis and v 2 -tests, respectively. DSS and OS were calculated from the date of diagnosis to the date of last follow up or death (based on the death certificate) using the Kaplan-Meier method, and comparisons were made with log-rank testing. Cox proportional hazard models were carried out to assess the influence of variables on OS and DSS. Only significant variables in the univariate analysis were included in the stepwise, forward, multivariable model. In order to determine the effects of ethnicity on outcome, a separate stepwise model including/excluding tumor characteristics was used to understand the incremental impact of each variable, a common practice in epidemiological studies. 16 Statistical significance was considered for P-values ≤0.05. Statistical analysis was carried out using SAS (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
A total of 2577 patients were included, of whom 2152 (83.5%) were non-Hispanic whites and 425 (16.5%) were Hispanic. Hispanics were diagnosed with RCC at a younger mean age compared with non-Hispanic whites (59 years vs 66 years, P < 0.001; Table 1 ). Overall, Hispanics were found to have a higher prevalence of comorbidities, such as CKD (2.6% vs 0.7%, P < 0.001) and diabetes (23.8% vs 15.9%, P < 0.001). The prevalence of obesity (BMI >30) was also higher among Hispanics compared with non-Hispanic whites (57.9% vs 43.5%, P = 0.0175), although BMI data were missing for most of the patients included in this investigation (2013 with missing BMI, including 1695 non-Hispanic whites and 318 Hispanics). In contrast, non-Hispanic white patients were more likely to have a recorded history of smoking (24.6% vs 20.2%), but this was not statistically significant (P = 0.0523). There were no significant differences between Hispanics and non-Hispanics for sex, hypertension or anemia.
Cancer characteristics
Substantial differences were found between Hispanics and non-Hispanic whites with respect to tumor characteristics. The histological types differed between groups (P < 0.044), with clear cell RCC more prevalent among Hispanics (88.9% vs 85%), whereas papillary RCC was more common among non-Hispanic whites (5.2% vs 1.2%). Hispanics were found to have lower AJCC stage at diagnosis than non-Hispanic whites, stage I/II in 67.4% vs 62.2%, respectively (P = 0.044). No statistical difference was found when comparing tumor size and grade, or TNM staging.
Cancer management and outcomes
Overall, Hispanics were more likely than non-Hispanic whites to receive surgery (84.2% vs 77.9%, P < 0.004). The rates of surgery between the two groups were similar for stage I/II disease (93% vs 92%, P = 0.01), but Hispanics were more likely to have surgical treatment for stage III/IV disease (65.5% vs 53.9%, P = 0.01). The median follow up for surviving patients was 66.7 and 63.2 months for Hispanics and non-Hispanic whites, respectively. A total of 83 (19.5%) and 495 (23%) Hispanics and non-Hispanic whites died from RCC during follow up. DSS was similar for both groups (P = 0.075; Fig. 1 ). The median OS was significantly improved on log-rank analysis for Hispanics (P = 0.023; Fig. 2 ). A univariate model identified significant predictors of DSS that were used for the multivariate model. On multivariate analysis of DSS (Table 2) , tumor grade (HR for grade I, 0.25, P < 0.001), AJCC III/IV staging (HR for grade III/IV, 7.65, P < 0.001), increased tumor size (HR 1.05, P < 0.001), non-surgical management (HR 5.74 for no surgery, P < 0.001) and Hispanic ethnicity (HR 1.38, P = 0.03) were all independent predictors of worse outcome. For OS, ethnicity did not appear to influence outcome in contrast to its effects on DSS. The stepwise analysis with tumor characteristics and treatment did not show ethnicity as a predictor of mortality (Table 3) .
Discussion
Racial and ethnic disparities in cancer incidence, disease characteristics, and mortality significantly differ in many cancers. These differences can be related to substantial differences in disease biology, but can be the result of issues with access to care and the acceptance of screening or likelihood of early diagnosis for symptoms within specific groups. Over the next three decades, the number of Hispanics is expected to triple in the USA, and will account for 30% of the population. 17 Therefore, it is imperative that we understand the current state of cancer in the Hispanic population. Although kidney cancer has received attention as being one of the cancers with significant differences by race/ethnicity in incidence and mortality, knowledge of potential differences in kidney cancer incidence, risk factors and outcomes in the Hispanic community have previously not been investigated.
In our evaluation of a large, diverse integrated healthcare system, we were able to examine the clinicopathological characteristics and survival outcomes for Hispanic and non-Hispanic white patients with kidney cancer. There were significant ethnic differences in patient and tumor characteristics, as well as outcome. Hispanic ethnicity was found to be an independent predictor of worse DSS when incorporating all prognostic variables. However, OS was not influenced by ethnicity despite the worse cancer-specific outcomes. As cancer stage has a significant impact on OS, it is likely that any ethnic influence on OS might be hidden in a cohort of individuals with mostly localized disease. Interestingly, Hispanic ethnicity was not associated with worse cancer outcomes, unadjusted for stage. The difference between the stage-adjusted and unadjusted analysis might be related to the observation that Hispanics were more likely to present with earlier-stage disease. There are multiple potential explanations for differences in cancer outcomes, including underlying biology, as well as differences in underlying risk factors; likelihood of presenting with symptoms, such as pain or hematuria; disease biology; and differences in selection of post-diagnostic treatment. Understanding these differences might be necessary to close an observed stage-specific survival gap, in addition to improving traditionally recognized social issues, such as early diagnosis and access to care. Other studies have tried to determine whether cancer biology differs for Hispanics compared with non-Hispanic whites. Hines et al. aimed to determine whether Hispanic and non-Hispanic white women presented with differing proportions of breast cancer phenotypic subtypes. 18 Clinical and pathological characteristics were compared by ethnic groups, and Hispanic women showed a greater frequency of tumors that were ER-negative and HER2-positive. 18 In fact, the odds of HER2 positivity were 2.8-fold higher in Hispanic patients, suggesting they might be more likely to benefit from therapy directed towards HER2, such as trastuzumab. 18 Altogether, these findings suggest that breast carcinoma in Hispanic women likely has a distinct underlying biology. Assessing these differences in disease biology and driver alterations between groups in other cancers, such as renal cell carcinoma, might yield results that help identify markers that lead to greater biological aggressiveness or direct treatment. In the Kaiser Permanente system, the availability of insurance, assigned primary care physicians, coordinated medical facilities, and clinical practice guidelines improve patients' access to care and appropriate, guideline-based treatment. Unlike past studies where surgical treatment rates were more equivalent across racial groups in a single healthcare system, Hispanics were actually found to have higher surgical rates within the current study, compared with non-Hispanic whites. 4 Controlling for access to care, variation in the rates of surgery might be due to differences in surgical candidacy, such as earlier stage disease, which was more common among Hispanics in the current study. This might also correlate with the fact that the age of diagnosis of kidney cancer was significantly younger in Hispanics when compared with non-Hispanic whites. Another issue could be related to the cultural acceptance of newer non-surgical treatment modalities, such as ablation or active surveillance. Recent work has suggested that minority groups might have differences in their decision-making regarding surgical treatment of early-stage cancer. 19 Therefore, decreased acceptance of active surveillance could account for an increased rate of treatment among Hispanics, although the current study cannot address the reasons for differences in treatment or why, despite aggressive surgical treatment, Hispanics had lower survival adjusted for stage.
Racial variation in histological subtype distribution has recently come to light in kidney cancer, as papillary kidney cancer is significantly enriched in the African American population. In our prior work involving the same Kaiser Permanente case-control study, the frequency of papillary RCC was nearly threefold greater among black individuals than among whites with kidney cancer. 4 The present results show that, even compared with non-Hispanic whites, Hispanics have an even lower incidence of papillary histology, as it accounted for just 1.2% of overall kidney cancer cases. Complex genetic or environmental factors might be associated with the distribution of histology types present in specific ethnic or racial groups. 20 Established risk factors for RCC include male sex, African American race, family history of kidney cancer, obesity, hypertension and smoking. 6 Obesity has been suggested to be more strongly associated with clear cell RCC than with other subtypes. 21 The present study found that Hispanics were more likely to be diagnosed with clear cell RCC, and it has already been well documented that there is a direct link between Hispanic ethnicity and the risk of obesity. 22 Despite participants earlier in the series having missing BMI data, Hispanics were more frequently overweight and obese (P = 0.0175). These observations suggest that a combination of genetic predispositions and environmental factors might be largely responsible for disease incidence and histological distribution.
To our knowledge, this is the first study that examines survival disparities among Hispanic patients with kidney cancer. By using a single regional healthcare system, we hoped to minimize extraneous variables, such as access to care, which could influence results. Unlike studies based only on cancer registry data, we included comorbidity data, such as CKD, which might be critical to survival analyses, as a recent paper suggests renal comorbidities account for much of the observed racial disparity in African Americans. 23 Besides influencing OS, comorbidities might influence specific treatment decisions and similarly affect cancer outcome.
The present analysis also had limitations, including several categories where there was missing data. BMI was only available for patients enrolled from 2005 to 2008, and therefore was missing for a large number of patients. However, as observed in our study for those with available BMI, the prevalence of obesity is higher among Hispanics compared with non-Hispanic whites in the general USA population. 22 Paradoxically, obesity has been consistently associated with improved RCC survival; 24 as such, the observed association between Hispanic ethnicity and RCC survival is likely to be a conservative estimate, and we would expect the association to be stronger if we had been able to control for BMI. Additionally, although tumor stage was widely available, tumor grade also had a large number of missing values, limiting the number of patients included in the multivariate analysis. Ethnicity is also a very complicated subject, and there are black people that have Hispanic ethnicity in the USA. While we had information on treatment, we did not have specifics on the type of surgery and utilization of systemic therapy at the time of recurrence -both of which could influence disease outcome.
Within a healthcare system with similar access to care, Hispanics with RCC were younger, had greater comorbidities and more frequently had clear cell RCC. Despite a lower AJCC stage, increased receipt of surgery and similar OS, Hispanic ethnicity was an independent predictor of worse disease survival. The present study suggests there might be disparities in kidney cancer survival outcomes between Hispanics and non-Hispanic whites that extend beyond issues related to access to care, and might include differences in disease biology or treatment. Further work is necessary to confirm this health disparity in other large datasets.
